SANES

10.812

+2.02%↑

BBVA

19.67

+0.36%↑

BNP

94.28

+1.26%↑

CABK

11.565

+0.96%↑

INGA

26.315

+0.59%↑

SANES

10.812

+2.02%↑

BBVA

19.67

+0.36%↑

BNP

94.28

+1.26%↑

CABK

11.565

+0.96%↑

INGA

26.315

+0.59%↑

SANES

10.812

+2.02%↑

BBVA

19.67

+0.36%↑

BNP

94.28

+1.26%↑

CABK

11.565

+0.96%↑

INGA

26.315

+0.59%↑

SANES

10.812

+2.02%↑

BBVA

19.67

+0.36%↑

BNP

94.28

+1.26%↑

CABK

11.565

+0.96%↑

INGA

26.315

+0.59%↑

SANES

10.812

+2.02%↑

BBVA

19.67

+0.36%↑

BNP

94.28

+1.26%↑

CABK

11.565

+0.96%↑

INGA

26.315

+0.59%↑

Home・Aktien・DBV Technologies SA

D
DBV Technologies SA

Open

2.954 -2.31

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.924

Max

3.042

Schlüsselkennzahlen
By Trading Economics
Einkommen	-2.4M -48M
EPS	-0.095
Gewinnspanne	-1,323.179
Angestellte	161
EBITDA	-4.1M -46M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+7.24% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	29. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-81M 958M
Vorheriger Eröffnungskurs	5.26
Vorheriger Schlusskurs	2.954

DBV Technologies SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Juni 2026, 21:51 UTC

Wichtige Markttreiber

Merlin Shares Rally After Defense Department's Design Review Wraps

4. Juni 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4. Juni 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4. Juni 2026, 23:42 UTC

Akquisitionen, Fusionen, Übernahmen

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4. Juni 2026, 23:41 UTC

Akquisitionen, Fusionen, Übernahmen

Energy Resources of Australia to Enter Trading Halt

4. Juni 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4. Juni 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Juni 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4. Juni 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4. Juni 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4. Juni 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. Juni 2026, 20:44 UTC

Akquisitionen, Fusionen, Übernahmen

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4. Juni 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4. Juni 2026, 20:15 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4. Juni 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4. Juni 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4. Juni 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4. Juni 2026, 18:47 UTC

Akquisitionen, Fusionen, Übernahmen

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4. Juni 2026, 18:38 UTC

Ergebnisse

Money Quote: Tech Weakness in Context -- WSJ

4. Juni 2026, 18:24 UTC

Ergebnisse

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4. Juni 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4. Juni 2026, 16:58 UTC

Ergebnisse

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4. Juni 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4. Juni 2026, 16:38 UTC

Ergebnisse

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4. Juni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4. Juni 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4. Juni 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4. Juni 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4. Juni 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Peer-Vergleich

Kursveränderung

DBV Technologies SA Prognose

Kursziel

By TipRanks

7.24% Vorteil

12-Monats-Prognose

Durchschnitt 3.26 EUR 7.24%

Hoch 5.5 EUR

Tief 1.01 EUR

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für DBV Technologies SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für DBV Technologies SA – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.